ProKidney Corp (NASDAQ:PROK)’s traded shares stood at 1.46 million during the last session, with the company’s beta value hitting 1.67. At the close of trading, the stock’s price was $0.61, to imply an increase of 5.32% or $0.03 in intraday trading. The PROK share’s 52-week high remains $4.44, putting it -627.87% down since that peak but still an impressive 24.59% since price per share fell to its 52-week low of $0.46. The company has a valuation of $179.57M, with an average of 1.15 million shares in intraday trading volume over the past 10 days and average of 547.89K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for ProKidney Corp (PROK), translating to a mean rating of 2.20. Of 6 analyst(s) looking at the stock, 0 analyst(s) give PROK a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.15.
ProKidney Corp (NASDAQ:PROK) trade information
After registering a 5.32% upside in the last session, ProKidney Corp (PROK) has traded red over the past five days. The 5-day price performance for the stock is -13.76%, and -38.01% over 30 days. With these gigs, the year-to-date price performance is -63.70%. Short interest in ProKidney Corp (NASDAQ:PROK) saw shorts transact 11.82 million shares and set a 21.39 days time to cover.
The extremes give us $3 and $6 for target low and target high price respectively. As such, PROK has been trading -883.61% off suggested target high and -391.8% from its likely low.
ProKidney Corp (PROK) estimates and forecasts
The rating firms project that company’s revenue will shrink -100.00% compared to the previous financial year.
PROK Dividends
ProKidney Corp has its next earnings report out on 2025-Mar-16. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ProKidney Corp (NASDAQ:PROK)’s Major holders
ProKidney Corp insiders hold 27.17% of total outstanding shares, with institutional holders owning 44.14% of the shares at 60.60% float percentage. In total, 44.14% institutions holds shares in the company, led by SUVRETTA CAPITAL MANAGEMENT, LLC. As of 2024-06-30, the company held over 9.34 million shares (or 12.306% of shares), all amounting to roughly $22.98 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 3.66 million shares, or about 4.8167% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $8.99 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO as the top two Mutual Funds with the largest holdings of the ProKidney Corp (PROK) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 2.97 shares. This is just over 2.29% of the total shares, with a market valuation of $1.82 million. Data from the same date shows that the other fund manager holds a little less at 2.92, or 2.26% of the shares, all valued at about 1.79 million.
